O76074 (PDE5A_HUMAN) Homo sapiens (Human)
cGMP-specific 3',5'-cyclic phosphodiesterase UniProtKBInterProSTRINGInteractive Modelling
875 aa; Sequence (Fasta) ; (Isoform 2)
It is possible new templates exist for this target since these models were created.
Available Structures
44 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine… |
Heteromer P18545; P51160; | 1×ZN; 1×MG; 3×IBM; | ||||
| Assess | ||||||
| Crystal structure of GAFb from the human phosphodiesterase 5 | homo-4-mer | |||||
| Assess | ||||||
| crystal structure of unliganded PDE5A GAF domain | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of PDE5A GAF domain (89-518) | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of Human Phosphodiesterase 5 complexed with tadalafil(Cialis) | homo-2-mer | 2×ZN; 2×MG; 2×CIA; | ||||
| Assess | ||||||
| Catalytic Domain Of Human Phosphodiesterase 5A | monomer | 1×ZN; 1×PO4; 1×CIT; | ||||
| Assess | ||||||
| Crystal structure of PDE5A1 in complex with icarisid II | monomer | 1×ZN; 1×MG; 1×7CA; | ||||
| Assess | ||||||
| Crystal structure of the catalytic domain of unliganded PDE5 | monomer | 1×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of PDE5 in complex with inhibitor 5R | monomer | 1×SO4; 1×24E; 1×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor | monomer | 1×ZN; 1×MG; 1×WAN; | ||||
| Assess | ||||||
| Crystal structure of PDE5A1-IBMX | monomer | 1×ZN; 1×MG; 1×IBM; | ||||
| Assess | ||||||
| Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafil | monomer | 1×VDN; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×5EO; 1×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of PDE5 in complex with sildenafil | monomer | 1×ZN; 1×MG; 1×VIA; | ||||
| Assess | ||||||
| Crystal structure of PDE5 in complex with inhibitor LW1634 | monomer | 1×ZN; 1×MG; 1×SO4; 1×9M0; | ||||
| Assess | ||||||
| Crystal structure of PDE5 in complex with inhibitor LW1805 | monomer | 1×SO4; 1×ZN; 1×MG; 1×9T9; | ||||
| Assess | ||||||
| Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafil | monomer | 1×ZN; 1×MG; 1×VIA; 1×GOL; | ||||
| Assess | ||||||
| Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafil | monomer | 1×ZN; 1×MG; 1×CIA; | ||||
| Assess | ||||||
| Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafil | monomer | 1×ZN; 1×MG; 1×VDN; | ||||
| Assess | ||||||
| Crystal structure of PDE5A in complex with CVT-313 | monomer | 1×MG; 1×ZN; 1×AJR; | ||||
| Assess | ||||||
| Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMP | monomer | 1×ZN; 1×MG; 1×5GP; | ||||
| Assess | ||||||
| Crystal structure of PDE5A in complex with a novel inhibitor | monomer | 1×MG; 1×ZN; 1×B0C; | ||||
| Assess | ||||||
| crystal structure of PDE5 in complex with a non-competitive inhibitor | monomer | 1×FZA; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×5CO; 1×ZN; 5×MG; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×5FO; 1×ZN; 3×MG; | ||||
| Assess | ||||||
| Human PDE5 catalytic core in complex with avanafil | monomer | 1×E6L; 1×ZN; 1×MG; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×5BA; 1×ZN; 1×MG; 2×PEG; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×5BB; 1×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of PDE5A in complex with a novel inhibitor | monomer | 1×ZN; 1×MG; 1×VZF; | ||||
| Assess | ||||||
| Crystal structure of Human Phosphodiesterase 5 complexed with Sildenafil(Viagra) | monomer | 1×ZN; 1×MG; 1×VIA; | ||||
| Assess | ||||||
| Crystal structure of PDE5A complexed with its inhibitor | monomer | 1×PEG; 1×ZN; 1×MG; 1×NI5; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×ZN; 1×MG; 1×5IO; | ||||
| Assess | ||||||
| Crystal structure of Human Phosphodiesterase 5 complexed with Vardenafil(Levitra) | monomer | 1×ZN; 1×MG; 1×VDN; | ||||
| Assess | ||||||
| Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafil | monomer | 1×ZN; 1×MG; 1×VIA; | ||||
| Assess | ||||||
| Investigation of Aminopyridiopyrazinones as PDE5 Inhibitors: Evaluation of Modifications to the Cen… | monomer | 1×PD4; 1×ZN; 2×MG; | ||||
| Assess | ||||||
| A novel series of potent and selective PDE5 inhibitor2 | monomer | 1×ZN; 1×MG; 1×0H3; | ||||
| Assess | ||||||
| Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | monomer | 1×5BO; | ||||
| Assess | ||||||
| A novel series of potent and selective PDE5 inhibitor1 | monomer | 1×ZN; 1×MG; 1×TGE; | ||||
| Assess | ||||||
| Crystal structure of PDE5A in complex with inhibitor L1 | monomer | 1×ZN; 1×MG; 1×SO4; 1×2OI; | ||||
| Assess | ||||||
| Crystal structure of PDE5A in complex with inhibitor L12 | monomer | 1×ZN; 1×MG; 1×2VI; | ||||
| Assess | ||||||
| PDE5A for NaV1.7 | monomer | 2×ZN; 1×6LK; | ||||
| Assess | ||||||
| Crystal structure of N2 substituted pyrazolo pyrimidinones - a flipped binding mode in PDE5 | monomer | 1×ZN; 1×MG; 1×3P4; 1×MES; | ||||
| Assess | ||||||
| Identification, Synthesis, and SAR of Amino Substituted Pyrido[3,2b]pryaziones as Potent and Select… | monomer | 1×PD6; 1×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of PDE5A in complex with its inhibitor | monomer | 1×NI0; 1×MG; 1×PEG; 1×ZN; | ||||
| Assess | ||||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3bjc.1.A | monomer | 0.82 | 1×ZN; 1×MG; 1×WAN; | 99.89 | ||
| Assess | ||||||
| 3lfv.1.A | homo-2-mer | 0.73 | 99.76 | |||
| Assess | ||||||
2 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 3bjc.1.A | monomer | 0.82 | 1×ZN; 1×MG; 1×WAN; | 99.88 | |
| Assess | ||||||
| Isoform 2 | 3lfv.1.A | homo-2-mer | 0.73 | 99.76 | ||
| Assess | ||||||